ACTB pseudogene 9 (ACTBP9)

ACTB pseudogene 9 is one of many pseudogenes related to the ACTB (actin beta) gene in the human genome[4][2]. Pseudogenes are noncoding sequences derived from ancestral genes, typically through duplication or retrotransposition, but lacking protein-coding capability due to disabling mutations or sequence divergence[6][8]. Some pseudogenes have been reported to regulate the expression of their parental gene, but most do not have established biological or clinical functions[6][8]. ACTB pseudogene 9 does not code for a protein, is not a direct therapeutic, diagnostic, or research target, and is not implicated in disease beyond potentially confounding genetic assays targeting ACTB due to high sequence similarity[4][7]. Pseudogenes like ACTB pseudogene 9 are numerous in the genome and are closely related in sequence to their parental gene (here, ACTB); in the case of ACTB, there are more than 60 such pseudogenes[4][2]. Pseudogenes, by definition, are nonfunctional as protein-coding genes[2][6]. They may occasionally act as competitive endogenous RNAs (ceRNAs) or have regulatory roles, but such functions are an exception and not established for ACTB pseudogene 9[6][8]. The main significance of ACTB pseudogenes is technical: they can interfere with PCR/qPCR assays meant to quantify ACTB transcript, leading to nonspecific amplification and inaccurate results[4][7]. ACTBP9 is not classified as a receptor, enzyme, transporter, transcription factor, or any other standard molecular family used in drug discovery. If you are seeking a classical protein-coding target or a therapeutic target, ACTB pseudogene 9 does not qualify and should not be listed as such.

Other names

ACTB PSG9